yamaha sports bike Maupay also had a dig at Everton when he departed on loan to Marseille in the summer and his latest taunt has further angered the Premier League club’s supporters. The 28-year-old said on X after Sean Dyche’s side had lost 2-0 to Nottingham Forest at Goodison Park on Sunday: “Whenever I’m having a bad day I just check the Everton score and smile.” Whenever I’m having a bad day I just check the Everton score and smile 🙂 — Neal Maupay (@nealmaupay_) Former boxer Tony Bellew was among the Toffees’ supporters who responded to Maupay, with the ex-world cruiserweight champion replying on X with: “P****!” Maupay endured a miserable spell at Everton, scoring just one league goal in 29 appearances after being signed by the Merseysiders for an undisclosed fee in 2022. He departed on a season-long loan to his former club Brentford for the 2023-24 season and left Goodison for a second time in August when Marseille signed him on loan with an obligation to make the deal permanent. After leaving Everton in the summer, Maupay outraged their fans by posting on social media a scene from the film Shawshank Redemption, famous for depicting the main character’s long fight for freedom.

CHICAGO — Scotty Pippen Jr. already had plenty of fond memories of watching his Hall of Fame father at the United Center. He added one of his own Saturday night. Pippen, son of former Bulls great Scottie, scored a career-best 30 points, added 10 assists and shot 13 of 16 to lead the Memphis Grizzlies past the Bulls, 142-131. “It’s a dream come true. It’s crazy to say I put up 30 and 10 in the gym where my dad had played,” he said after scoring 26 points in the first three quarters to help Memphis win its second straight. “It means everything to me and my family. I talked to my dad tonight about coming in here and playing. He just told me to go out there and kill it, so that’s what I tried to do.” The elder Pippen wasn’t in the building Saturday night but was in Memphis on Nov. 8 when his son finished with 11 points, 10 rebounds and 11 assists. It made the father and son the only such duo to each record triple-doubles. Two-time All-Star Ja Morant’s absence with a hip injury – he missed his eighth straight game – has certainly helped Pippen find his niche during his second season in the NBA. On Saturday, he was effective from the perimeter, in transition and finding space in the paint. “Scotty Pippen was phenomenal tonight,” Grizzlies coach Taylor Jenkins said. Memphis Grizzlies' Scotty Pippen Jr. posts up on Chicago Bulls' Jalen Smith as Coby White handles the ball during the first half of an NBA basketball game Saturday, Nov. 23, 2024, in Chicago. Credit: AP/Charles Rex Arbogast The younger Pippen started the night averaging 11.6 points and 5.7 assists in the team’s first 17 games.

The scene outside the shop was a flurry of activity, with cameras flashing and fans calling out Xiang Zuo's name. The star graciously posed for photos and signed autographs, making sure to acknowledge each and every fan who had come out to show their support.

If you've been looking for a sweet deal on an iPad, we got you covered. Apple's flagship tablets rarely see sales, but with Black Friday behind us and the holidays fast approaching, Walmart has one of the best deals on the 10th-generation iPad we've seen all year. The 10th Gen, released in 2022, is Apple's base-model iPad. It boasts substantial upgrades, like symmetrical bezels, a larger 10.9-inch display, Magic Keyboard Folio support, and the latest software version, iPadOS 16. Also: The 16 best tech stocking stuffers perfect for holiday gifting (and many are on sale now) Apple also moved the fingerprint sensor to the outer edge, and dual speakers flank the left and right sides when the tablet is held in landscape orientation. The best part? The whole unit weighs approximately one pound. ZDNET's Kerry Wan went hands-on with the iPad 10th Gen in 2022 and was impressed with Apple's upgrades to its base model. He continued using the tablet well into 2023, updating his review in May of that year. Following Apple's Worldwide Developers Conference in June, the iPad 10th Gen got a permanent price drop to $349 , and right now, you can swipe it up for $279 at Walmart, a savings of $70. Just note that the sale only applies to the iPad 10th Gen (64GB) in Blue or Silver, with other colorways sticking to the regular price of $330. This beats Amazon's $299 price we saw during this past July Prime Day, which when it dropped was one of the best deals we had seen for 2022's flagship Apple tablet. Remember, Apple products don't frequently see price cuts, and with the holiday season just around the corner, this iPad deal may be selling quick. Review : iPad 10th Gen (2022) "My 'first impressions' hot take is still ablaze: the iPad beats out the iPad Pro model in two regards. The first is Apple's own accessories. The second area where the regular iPad edges out the Pro is camera placement," Wan wrote in his review. If you're looking to snag the 10th Gen iPad , which Wan says stacks up pretty well against the more expensive iPad Air, be sure to jump on this sweet deal while it lasts. When will this deal expire? Deals are subject to sell out or expire at any time, though ZDNET remains committed to finding, sharing, and updating the best product deals for you to score the best savings. Our team of experts regularly checks in on the deals we share to ensure they are still live and obtainable. We're sorry if you've missed out on this deal, but don't fret -- we're constantly finding new chances to save and sharing them with you at ZDNET.com . Best Cyber Monday deals Best Cyber Monday TV deals Best Cyber Monday streaming deals Best Cyber Monday AirPods dealsSingle heat wave wiped out millions of Alaska's dominant seabird

Israeli Prime Minister Benjamin Netanyahu —AP Photo/Maya Alleruzzo, Pool, File TEL AVIV, Israel — Israeli Prime Minister Benjamin Netanyahu underwent successful surgery Sunday to have his prostate removed, hospital officials said, a procedure that came as he manages multiple crises including the war in Gaza and his trial for alleged corruption. Netanyahu, who has had a series of health issues in recent years, has gone to great lengths to bolster a public image of himself as a healthy, energetic leader. During his trial this month, he boasted about working 18-hour days, accompanied by a cigar. But as Israel’s longest-serving leader, such a grueling workload over a total of 17 years in power could take a toll on his well-being. Netanyahu, 75, is among older world leaders including US President Joe Biden, 82, President-elect Donald Trump, 78, Brazil’s President Luiz Inácio Lula da Silva, 79, and Pope Francis, 88, who have come under scrutiny for their age and health issues. Netanyahu’s latest condition is common in older men, but the procedure has had some fallout. The judges overseeing his trial accepted a request from his lawyer on Sunday to call off three days of testimony scheduled this week. The lawyer, Amit Hadad, had argued that Netanyahu would be fully sedated for the procedure and hospitalized for “a number of days.” Jerusalem’s Hadassah Medical Center announced late Sunday that the procedure had been completed successfully and that the prime minister had woken up. Netanyahu thanked his doctors. His office said he was “fully alert” and was taken to an underground recovery unit fortified against potential missile attacks. Netanyahu was expected to remain in the hospital for several days of observation. Justice Minister Yariv Levin, a close ally, served as acting prime minister during the operation. With so much at stake, Netanyahu’s health in wartime is a concern for both Israelis and the wider world. As Israel’s leader, Netanyahu is at the center of major global events that are shifting the Middle East. With the dizzying pace of the past 14 months, being incapacitated for even a few hours can be risky. Netanyahu will be in the hospital at a time when international mediators are pushing Israel and Hamas to reach a ceasefire in Gaza and as fighting between Israel and Yemen’s Iran-backed Houthi rebels intensifies. Prostate issues are common and in many cases easily treatable. Still, the procedure puts a dent in Netanyahu’s image of vigor at a time when he would want to project strength more than ever, both to an Israeli audience navigating constant threats as well as to Israel’s enemies looking to expose its weaknesses. Netanyahu insists he is in excellent health. His office releases footage of him touring war zones in full protective gear flanked by military officers, or meeting with defense officials on windswept hilltops in youthful dark shades and puffer jackets. But that image was shattered last year when Netanyahu’s doctors revealed that he had a heart condition, a problem that he had apparently long known about but concealed from the public. A week after a fainting spell, Netanyahu was fitted with a pacemaker to control his heartbeat. Only then did staff at the Sheba Medical Center reveal that Netanyahu has for years experienced a condition that can cause irregular heartbeats. The revelation came as Netanyahu was dealing with massive anti-government protests. The news about a chronic heart problem stoked further anger and distrust during extreme political polarization in Israel. Last year, Netanyahu was rushed to the hospital for what doctors said likely was dehydration. He stayed overnight, prompting his weekly Cabinet meeting to be delayed. Earlier this year, Netanyahu underwent hernia surgery, during which he was under full anesthesia and unconscious. Levin served as acting prime minister during the operation. According to Netanyahu’s office, the Israeli leader was diagnosed with a urinary tract infection on Wednesday stemming from a benign enlargement of his prostate. The infection was treated successfully with antibiotics, but doctors said the surgery was needed in any case. Complications from prostate enlargement are common in men in their 70s and 80s, Dr. Shay Golan, head of the oncology urology service at Israel’s Rabin Medical Center, told Israeli Army Radio. Golan spoke in general terms and was not involved in Netanyahu’s care or treatment. He said an enlarged prostate can block proper emptying of the bladder, leading to a build-up of urine that can lead to an infection or other complications. After medicinal treatment, doctors can recommend a procedure to remove the prostate to prevent future blockages, Golan said. In Netanyahu’s case, because the prostate is not cancerous, Golan said doctors were likely performing an endoscopic surgery, carried out by inserting small instruments into a body cavity, rather than making surgical cuts in the abdomen to reach the prostate. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . The procedure lasts about an hour, Golan said, and recovery is quick. He said that aside from catheter use for one to three days after the procedure, patients can return to normal activity without significant limitations. —APHowever, there is one actress who holds a special place in Zhang Yimou's heart - Sophie Marceau. The French actress, known for her beauty, elegance, and versatility, has collaborated with Zhang on several occasions, creating magic on the screen that transcends language and cultural barriers.

NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global heparin market size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.22% during the forecast period. Increasing prevalence of coagulation disorders is driving market growth, with a trend towards increasing R and D activities and new therapeutic applications of heparin. However, side effects of heparin poses a challenge. Key market players include Aspen Pharmacare Holdings Ltd, B.Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., Viatris Inc., Opocrin SpA, Pfizer Inc.; GlaxoSmithKline plc; Sandoz (Novartis AG) Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Heparin market is experiencing significant growth due to the rising prevalence of venous thromboembolism (VTE) and blood clotting disorders. VTE includes deep vein thrombosis and pulmonary embolism, which can lead to serious complications like heart attacks and strokes. Heparin, an injectable anticoagulant, is widely used to prevent blood clotting in veins and arteries. Both unfractionated heparin, derived from animal sources like bovine and porcine, and plasma-derived therapies (PDTs) are popular. However, challenges like fungal infections, counterfeit drugs, and chronic diseases such as diabetes, cancer, and cardiovascular diseases (CVD) increase the market demand. The geriatric population, accident victims, and those with orthopedic disorders are significant patient groups. Heparin is administered via subcutaneous injection or intravenous infusion, depending on the condition. Major players include Baxter International's Optimvia, which offers both bovine and porcine heparin. Other applications include atrial fibrillation and thromboprophylaxis. Heparin, discovered in 1961, is a universal anticoagulant used to treat hemostasis and thrombosis. Its applications in surgery, interventions, and medicine have significantly impacted healthcare. Major advancements include fractionated heparin and low-molecular-weight heparin, expanding thrombosis management options. These developments have revolutionized scientific approaches to heparin use. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Heparin, an injectable anticoagulant, plays a crucial role in preventing blood clotting in individuals at risk of venous thromboembolism (VTE), including those with accidents, blood clotting disorders, and chronic diseases like cardiovascular diseases (CVD), cancer, chronic respiratory diseases, diabetes, and atrial fibrillation. However, challenges persist in ensuring patient safety. These include the risk of VTE in the geriatric population and those with orthopedic disorders. Unfractionated heparin, derived from animal sources like bovine and porcine, faces challenges such as fungal infections and counterfeit drugs. PDTs like Optimvia offer alternatives, but come with their own risks, including bleeding and allergic reactions. Proper administration, whether subcutaneous or intravenous, is essential to mitigate risks. Intravenous infusion and subcutaneous injection are common methods, while deep vein thrombosis conditions like pulmonary embolism and heart attacks require immediate attention. Overall, addressing these challenges is vital to improving patient outcomes and ensuring the safety and efficacy of heparin treatments. Heparin, an anticoagulant discovered in the 1930s, is widely used to prevent and treat thrombosis, a condition characterized by the formation of blood clots. While heparin's efficacy is undeniable, its use comes with notable side effects. The most significant risks include bleeding, heparin-induced thrombocytopenia, osteoporosis, skin reactions, eosinophilia, and allergic reactions. Among these, bleeding and thrombocytopenia are the most common concerns. Despite these challenges, heparin remains the preferred anticoagulant for acute thrombotic incidents due to its proven effectiveness. New anticoagulant drugs are under development, but heparin's long-standing reputation and usage make it a crucial player in the anticoagulant market. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This heparin market report extensively covers market segmentation by 1.1 Low-molecular-weight heparin 1.2 Others 2.1 Subcutaneous injection 2.2 Intravenous infusion 3.1 Europe 3.2 North America 3.3 Asia 3.4 Rest of World (ROW) 1.1 Low-molecular-weight heparin- Low-molecular-weight heparin (LMWH) is a type of heparin derived from unfractionated heparin through chemical or enzymatic methods. It inhibits coagulation by activating antithrombin III, preventing the activation of factor Xa and subsequent conversion of prothrombin to thrombin, and the formation of fibrin from fibrinogen. LMWH has several advantages over unfractionated heparin, including improved bioavailability, prolonged antithrombotic activity, and reduced need for regular blood monitoring. The British National Formulary and the National Institute for Health and Care Excellence have approved LMWH for various clinical indications, including deep vein thrombosis prophylaxis in medium- and high-risk groups, treatment of deep vein thrombosis and pulmonary embolism in nonpregnant women, treatment of venous thromboembolism in pregnancy, treatment of ST-elevation myocardial infarction in patients undergoing percutaneous coronary intervention, and prevention of clotting in extracorporeal circuits. Unfractionated heparin and LMWH are self-administered subcutaneously. Several LMWH options are available in the market, including Fragmin (dalteparin), Lovenox (enoxaparin), parnaparin, certoparin, nadroparin, reviparin, and bemiparin. Each product has unique advantages, such as improved bioavailability, longer half-life, and lower incidence of adverse effects. For instance, dalteparin has a mean molecular weight of approximately 5,000 Da, improved bioavailability, and a lower incidence of heparin-induced thrombocytopenia and thrombosis. Lovenox (enoxaparin) is associated with a low incidence of adverse effects and a reduced need for laboratory monitoring. Parnaparin has greater efficacy, greater bioavailability, and a longer half-life, permitting once-daily administration. Certoparin has been proven effective and safe in preventing venous thromboembolism in different medical and surgical settings. Nadroparin has a greater ratio of anti-factor Xa to anti-factor Ha activity, greater bioavailability, and a longer duration of action. Reviparin has a narrow molecular weight distribution profile and is effective in preventing deep vein thrombosis at different daily doses. Bemiparin has the lowest mean molecular weight, the longest half-life, and the largest anti-factor Xa activity, making it effective in preventing venous thromboembolism in moderate- and high-risk surgical patients and during hemodialysis. The wide availability of LMWH products and their advantages and efficacy increase the adoption of LMWH, contributing to the growth of the LMWH segment in the global heparin market during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Heparin market refers to the global trade of Heparin, an essential injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is primarily used to manage Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins, which can lead to serious complications like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Accidents, chronic blood diseases such as diabetes, and the elderly demographic are significant risk factors for VTE. Heparin is also used to prevent arterial thromboembolism and is crucial in the blood donation system to prevent clotting. Unfractionated heparin, an animal-derived product, is the most commonly used form of heparin. Plasma-derived therapies (PDTs) are alternative options. Heparin is administered through subcutaneous or intravenous (IV) methods and is used to manage conditions like Atrial Fibrillation and blood clotting disorders. Market Research Overview The Heparin market refers to the global trade of heparin, an injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is primarily used to manage Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins, which can lead to complications such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Heparin is also used to prevent clots in arteries, particularly in patients with conditions like atrial fibrillation, heart attacks, and strokes. This drug is derived from animal sources, including porcine and bovine, and is administered either subcutaneously or intravenously. Heparin is essential in managing chronic diseases like diabetes, cancer, and chronic respiratory diseases, as well as noncommunicable diseases (NCDs) and cardiovascular diseases (CVD). However, the market faces challenges such as counterfeit drugs, fungal infections, and the risk of bleeding. The geriatric population and patients with orthopedic disorders are significant consumer groups. Heparin comes in different forms, including Unfractionated Heparin and Plasma-derived therapies (PDTs). It is used in clinics for various indications, including subcutaneous administration for DVT prevention and intravenous infusion for acute PE treatment. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Product Low-molecular-weight Heparin Others Route Of Administration Subcutaneous Injection Intravenous Infusion Geography Europe North America Asia Rest Of World (ROW) Type Application End-use Source 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio